STAT3 and neoplasm: Similarly, activated SRC is found in 36% of primary ovarian cancers, and inhibiting SRC can reduce tumor growth (49), suggesting that in addition to blocking DNA damage repair, targeting both STAT3 and SRC in tumor cells can be an advantage of Niraparib over Olaparib.